Ipamorelin vs Macimorelin

Ipamorelin and Macimorelin are both growth hormone secretagogues (GHS) that activate the ghrelin receptor (GHS-R1a) to stimulate pituitary GH release, but they serve fundamentally different research purposes. Ipamorelin is a synthetic pentapeptide designed for high selectivity, minimizing off-target effects on cortisol, prolactin, and appetite. It is primarily investigated in preclinical models for its potential to modulate body composition, recovery, and aging-related processes. In contrast, Macimorelin is an orally bioavailable small molecule that received FDA approval in 2017 as a diagnostic test for adult growth hormone deficiency (AGHD). Its development was driven by the need for a safer, more convenient alternative to the insulin tolerance test. These divergent paths—one as a research tool for physiological modulation, the other as a validated clinical diagnostic—underscore the importance of matching peptide choice to experimental objectives.

Ipamorelin stands out as the most selective growth hormone secretagogue currently available, characterized as a synthetic pentapeptide (MW ~711.86 g/mol, formula C38H49N9O5). Its mechanism involves binding to the ghrelin receptor, leading to the pulsatile release of GH from the pituitary gland. Notably, research has shown that Ipamorelin does not significantly elevate levels of cortisol, prolactin, or appetite-regulating hormones, positioning it as a 'mild' GHS in preclinical studies. Investigations have primarily focused on its potential roles in anti-aging, body composition enhancement (such as lean mass preservation), and recovery from injuries or stress. However, the existing evidence base is predominantly derived from small animal studies and limited human trials. As of now, Ipamorelin is not FDA-approved for any specific indication, and while its favorable side-effect profile makes it an appealing research tool, the absence of large-scale, randomized controlled trials limits the conclusiveness of its efficacy.

Macimorelin (brand name Macrilen) is notable for being the only orally active growth hormone secretagogue approved by the FDA, receiving this designation in December 2017 for the diagnosis of adult growth hormone deficiency (AGHD). Its mechanism involves stimulating GH release, with the resulting peak GH response measured to confirm GH deficiency. The development of Macimorelin was driven by the need for a safer and more convenient alternative to the insulin tolerance test (ITT), which had been the gold standard for diagnosing AGHD. Clinical trials have demonstrated that Macimorelin exhibits a 92% concordance rate with the ITT, affirming its diagnostic reliability. The compound was initially developed by Aeterna Zentaris, with marketing rights held by Novo Nordisk until 2022. This established role in clinical diagnostics underscores Macimorelin's importance in the assessment of GH levels in patients rather than therapeutic applications.

Though both Ipamorelin and Macimorelin target growth hormone release, their applications in research are distinctly defined, with limited overlap. Ipamorelin is primarily utilized in preclinical and early-phase studies aimed at exploring its effects on anti-aging, body composition (including muscle preservation and reduction of adiposity), and recovery from physical stressors. Its selective action allows researchers to investigate the physiological roles of GH in tissue repair and metabolic processes. In contrast, Macimorelin is exclusively employed in clinical diagnostic research for adult growth hormone deficiency (AGHD), serving as a validated agent for GH stimulation testing. This differentiation means that Macimorelin is not typically studied for therapeutic outcomes such as body composition changes or anti-aging effects. Consequently, researchers must align their choice of peptide with their specific experimental focus: Ipamorelin for mechanistic studies in aging or metabolism, and Macimorelin for diagnostic accuracy in GH deficiency screening.

Ipamorelin is often regarded as the mildest growth hormone secretagogue available, with a favorable safety profile noted in both animal and human studies. Reported adverse events are generally mild and primarily associated with injection site reactions, such as redness, swelling, or bruising, affecting approximately 15–30% of users and typically resolving within 24–48 hours. Some individuals may experience transient effects such as a mild 'head rush' or flushing due to vasodilation following injection. Importantly, no significant elevations in cortisol, prolactin, or glucose levels have been consistently observed. Conversely, Macimorelin, used as a single-dose diagnostic agent, is generally well tolerated, with common adverse reactions (occurring in ≥1% of cases) including dysgeusia (taste disturbance), dizziness, headache, fatigue, and nausea. Notably, transient QTc prolongation has been reported, warranting caution in patients with pre-existing QT prolongation or those on QT-prolonging medications. The distinct safety profiles of these two compounds reflect their differing applications: Ipamorelin for repeated administration in research settings, and Macimorelin for single-dose use in diagnostic evaluations.